New intravenous combination antibiotic for intra-abdominal and urinary tract infection

Zerbaxa contains the cephalosporin ceftolozane and the beta-lactamase inhibitor tazobactam.

Ceftolozane/tazobactam is effective against bacteria including Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae. | iStock

Further information
View Zerbaxa drug record 
Summary of Product Characteristics
Manufacturer: Merck Sharp & Dohme

The combination is administered by intravenous infusion and is indicated for the treatment of complicated intra-abdominal infection, complicated urinary tract infection and acute pyelonephritis. Susceptible organisms include Enterobacter cloacae, Escherichia coli and Klebsiella pneumoniae.

In a trial in patients with complicated intra-abdominal infection, clinical cure rates for the ceftolozane/tazobactam combination were 95.9% in patients younger than 65 years (n=293) and 87.8% in those 65 years or older (n=82).

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

An empty tablet blister pack.

Ezetimibe supply update

Availability issues have been reported for the lipid-lowering...

Woman holding blister strip of contraceptive pills

Pharmacists across England to initiate oral contraceptives

Pharmacy Contraception Service (PCS) could allow almost...